Related references
Note: Only part of the references are listed.Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Yingjun Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice
Wen-juan Hu et al.
ACTA PHARMACOLOGICA SINICA (2021)
Remdesivir against COVID-19 and Other Viral Diseases
Jakob J. Malin et al.
CLINICAL MICROBIOLOGY REVIEWS (2021)
Characteristics of SARS-CoV-2 and COVID-19
Ben Hu et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs
Jun Shi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?
Wim Van Damme et al.
MEDICAL HYPOTHESES (2021)
COVID-19: Characteristics and Therapeutics
Rameswari Chilamakuri et al.
CELLS (2021)
Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies
Silke Gastine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients
Marco Contoli et al.
FRONTIERS IN IMMUNOLOGY (2021)
COVID-19: Why does disease severity vary among individuals?
Saeed Samadizadeh et al.
RESPIRATORY MEDICINE (2021)
Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness
Ashesha Mechineni et al.
EXPERT OPINION ON DRUG SAFETY (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
Qiurong Ruan et al.
INTENSIVE CARE MEDICINE (2020)
Characteristics of COVID-19 infection in Beijing
Sijia Tian et al.
JOURNAL OF INFECTION (2020)
Quantitative computed tomography analysis for stratifying the severity of Coronavirus Disease 2019
Cong Shen et al.
JOURNAL OF PHARMACEUTICAL ANALYSIS (2020)
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
Yvan Jamilloux et al.
AUTOIMMUNITY REVIEWS (2020)
Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019
Jianghong Fan et al.
CLINICAL INFECTIOUS DISEASES (2020)
Type I IFN immunoprofiling in COVID-19 patients
Sophie Trouillet-Assant et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2
Daniel J. Jackson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
Jin Liu et al.
EBIOMEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19
Sarah C. J. Jorgensen et al.
PHARMACOTHERAPY (2020)
Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (BARS-CoV-2) Patients with Outcome and Symptoms
Kimon Argyropoulos et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Ka-Tim Choy et al.
ANTIVIRAL RESEARCH (2020)
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects
Rita Humeniuk et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity
Maria Pilar Guallar et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Mild versus severe COVID-19: Laboratory markers
Thirumalaisamy P. Velavan et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
Andrea J. Pruijssers et al.
CELL REPORTS (2020)
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
Remo H. M. Furtado et al.
LANCET (2020)
An inflammatory cytokine signature predicts COVID-19 severity and survival
Diane Marie Del Valle et al.
NATURE MEDICINE (2020)
Challenges for Drug Repurposing in the COVID-19 Pandemic Era
Janet Sultana et al.
FRONTIERS IN PHARMACOLOGY (2020)
COVID-19: A Risk Assessment Perspective
Imke Schroder
ACS CHEMICAL HEALTH & SAFETY (2020)
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load
Antonio Goncalves et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance
[Anonymous]
PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE (2020)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling
Z. Li et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
Dynamics of Influenza Virus Infection and Pathology
Roberto A. Saenz et al.
JOURNAL OF VIROLOGY (2010)
Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection
Ha Youn Lee et al.
JOURNAL OF VIROLOGY (2009)
Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1
R Gazit et al.
NATURE IMMUNOLOGY (2006)
Treatment of SARS with human interferons
J Cinatl et al.
LANCET (2003)
Share Paper
